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A B S T R A C T
Aims: It is unclear how the prevalence of diabetes in Asian Indians in urban India compares to that of
race/ethnic groups in the US that may have different underlying susceptibilities. Therefore, we exam-
ined ethnic variations in the prevalence of type 2 diabetes, iIFG, iIGT, IFG + IGT, and the associated risk
factors in Asian Indians in Chennai, India, and Whites, Blacks, and Hispanics in the United States.
Methods: Cross-sectional analyses, using representative samples of 4867 Asian Indians aged 20–74 years
from Chennai, India, in the Centre for Cardiometabolic Risk Reduction in South-Asia study (CARRS) (2010–
2011) and 6512 USWhites, Blacks, and Hispanics aged 20–74 years from the National Health and Nutrition
Examination Survey (NHANES) (2007–2012).
Results: The age-adjusted prevalence of type 2 diabetes was highest in Asian Indians (men: 28.4, 95%
CI: 25.9, 31.0; women: 30.6, 95% CI, 27.5, 33.9) and lowest in Caucasians (men: 12.2, 95% CI, 10.3, 14.4,
women: 9.5, 95% CI, 7.9, 11.5). Asian Indians had the lowest prediabetes prevalence (men: 19.0, 95% CI,
17.2, 20.8; women: 27.2, 95% CI, 22.8, 32.1) and Caucasians had the highest (men; 46.5, 95% CI, 43.5, 49.6,
women: 34.4, 95% CI, 31.7, 37.3). However, there were differences in prediabetes prevalence by gender
and prediabetes state. The inclusion of HOMA-β in standardized polytomous logistic regression models
resulted in a greater odds of diabetes in Blacks and Hispanics compared to Asian Indians.
Conclusions: The high prevalence of diabetes in Asian Indians may be due to innate susceptibilities for
β-cell dysfunction in this high risk population.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Type 2 diabetes mellitus (diabetes) is a complex metabolic dis-
order that involves both impaired insulin action and impaired insulin
secretion. Traditionally, the pathophysiology has been described as
age- or obesity-induced insulin resistance followed by a decrease
in compensatory pancreatic β-cell response, eventually leading to
overt hyperglycemia [1,2]. For the last three decades, India has ex-
perienced rapid increases in the prevalence of diabetes [3,4] that
have occurred alongside concurrent economic, epidemiological, and
nutritional transitions [5–7]. While some of the high diabetes burden
in India can likely be attributed to urbanization and the conse-
quent obesogenic changes in patterns of food consumption and
physical inactivity [6], it is also possible that Asian Indians expe-
rience unique biological susceptibilities to diabetes development,
such as impaired pancreatic insulin secretion early in the natural
history of disease [8–10]. These unique susceptibilities, coupled with
factors related to the changing landscape in urban India, may be
the driving factors behind the high risk in this race/ethnic group.
However, it is unclear as to how the prevalence of diabetes in
Asian Indians living in rapidly transitioning urban India currently
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compares to that of other race/ethnic groups in a developed country
such as the United States who are also at high risk but may develop
diabetes through different physiological mechanisms such as obesity-
driven insulin resistance. We, therefore, examined the age-speciﬁc
prevalence of diabetes and its precursor states of isolated im-
paired fasting glucose (iIFG), isolated impaired glucose tolerance
(iIGT) and combined impaired fasting glucose and impaired glucose
tolerance (IFG + IGT), and the associated risk factors in a population-
based sample of Asian Indians living in Chennai, India, and compared
them to several race/ethnic groups living the United States.
Materials and methods
In brief, The Center for Cardiometabolic Risk Reduction in South
Asia study (CARRS) is a multi-site, cross-sectional surveillance study
consisting of two urban cities in India and one in Pakistan. Recruit-
ment and data collection were conducted between 2010 and 2011
[11]. For the purposes of this study, data were analyzed from the
Chennai, India, site only, as this was the only site to collect both
fasting and two hour plasma glucose samples. Chennai is a metro-
politan city located in the South Indian state of Tamil Nadu with a
population of approximately 4.68 million people [12]. Households
were selected for participation using multi-stage random sam-
pling technique in order to be representative of Chennai [11]. A total
of 6920 individuals aged ≥20 were screened for participation, of
which 6906 (99%) provided questionnaire data and 876 (13%) re-
ported a previous diabetes diagnosis. Fasting plasma glucose was
obtained from 5952 participants (86%). In those not reporting a pre-
vious diabetes diagnosis (6030), two hour post-challenge glucose
was obtained from 4051 participants (67%). For this studywe limited
our population to the 4867 (70%) participants who were either pre-
viously diagnosed with diabetes or who provided fasting and two
hour post-challenge glucose measurements. All participants in
CARRS-Chennai were considered Asian Indian.
The National Health and Nutrition Examination Survey (NHANES)
is a cross-sectional complex sample survey conducted by the US
Centers for Disease Control and Prevention’s National Center for
Health Statistics. The survey is designed to be representative of the
US civilian, non-institutionalized population on the basis of a
complex multi-stage, biennial probability sample [13]. After com-
pleting an in home questionnaire, participants attended a mobile
examination clinic where they received a questionnaire as well as
physical and laboratory measurements. Cycles 2007–2008, 2009–
2010, and 2011–2012 were combined for analysis. A total of 24,731
participants aged ≥20 were screened for participation. Of those,
17,713 (72%) provided questionnaire data, and 17,085 (69%) par-
ticipated in the mobile examination. Participants who self-reported
as “other ethnicity” (1542 (9%)) or whowere currently pregnant (116
(0.7%)) were excluded from analysis. We also excluded 1776 (10%)
participants who were over the age of 75 to remain in concor-
dance with the upper age group included in CARRS. Of the remaining
14,279 participants, 1749 participants (12%) were previously diag-
nosed with diabetes. Fasting plasma glucose values were obtained
from 6399 and two hour post-challenge glucose values were ob-
tained from 4763 participants. We thus limited our population to
the 6512 individuals who met inclusion criteria and had either a
previous diabetes diagnosis or gave both fasting and two hour post
challenge glucose measurements, and self-identiﬁed as either
Mexican American (Hispanic), Other Hispanic (Hispanic), Non-
Hispanic Caucasian (White), or Non-Hispanic Black (Black). Details
regarding the eligibility criteria, questionnaire, and examination com-
ponents in NHANES and CARRS are listed in Table 1. Additional
details of each study have been previously published [11,13].
In both the CARRS and NHANES studies, type 2 diabetes was
deﬁned by previous physician diagnosis, the use of glucose lower-
ing medication, or fasting plasma glucose ≥7.0 mmol/L and/or two
hour post-challenge glucose ≥11.1mmol/L [14]. Both individuals with
previously diagnosed diabetes or diabetes that was newly
Table 1
Eligibility, questionnaire and exam components in NHANES and CARRS used for analysis
NHANES CARRS
Eligibility criteria
Inclusion criteria • Civilian, non-institutionalized individuals, aged 20 years or older
living in the US
• Aged 20 years or older and permanently residing in
the selected household
Exclusion criteria • Pregnant women
• Hemophilia
• Chemotherapy within the last 4 weeks
• The presence of rashes, gauze dressings, casts, edema, paralysis, tubes,
open sores or wounds, withered arms or limbs missing, damaged, sclerosed
or occluded veins, allergies to cleansing reagents, burned or scarred tissue,
shunt or intravenous lines on both arms
• Participants aged ≥75 years
• Pregnant women
• Bed-ridden individuals
• Participants aged ≥75 years
Questionnaires • Demographic information including race/ethnicity, family history of
type 2 diabetes mellitus medical history, and current medication use
• Demographic information including language use,
family history of type 2 diabetes mellitus, medical
history, and current medication use
Weight • Digital ﬂoor scale with automated data capture and read out capabilities • Standing balance beam scale
Height • Wall mounted stadiometer • Portable stadiometer
Waist circumference • Flexible tape measure at uppermost lateral border of the right ilium and
the midaxillary line
• Non-stretch measuring tape at the site of maximum
circumference halfway between the lower ribs and
the anterior superior iliac spine
Phlebotomy • Conducted by certiﬁed phlebotomists
• 100 mL of blood in the fasting state to measure glucose, insulin, and lipids
• After a 9 hour overnight fast, a 75 g oral glucose tolerance test (OGTT)
• Obtained from a peripheral vein just before glucose ingestion (time 0) and
then 120 minutes post-challenge for participants who performed the (OGTT)
• Conducted by certiﬁed phlebotomists.
• 15 mL of blood in the fasting state to measure
glucose, insulin and lipids
• After at least a 9 hour overnight fast, a 75g OGTT
• Obtained from a peripheral vein just before glucose
ingestion (time 0) and at 30 and 120 minutes post
glucose challenge
• The samples were transported from ﬁeld sites in cold
chain to laboratories for analysis
Glucose • Serum glucose was measured using the hexokinase method • Serum glucose was measured using the hexokinase method
NHANES = National Health and Nutrition Examination Survey; CARRS = Center for Cardiometabolic Risk Reduction Survey; OGTT = Oral Glucose Tolerance Test.
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detected were included in the analysis. Given that the precursor
states of diabetes, iIFG, iIGT and IFG + IGT have different etiologi-
cal and pathophysiological mechanisms [15,16], each state was
analyzed separately. iIFG was deﬁned by fasting plasma glucose of
5.6–6.9 mmol/L with normal two hour-post challenge glucose. iIGT
was deﬁned as normal fasting plasma glucose with two hour post-
challenge glucose of 7.8–11.0 mmol/L. Combined IFG + IGT was
deﬁned as both fasting plasma glucose of 5.6–6.9 mmol/L and two
hour post-challenge glucose of 7.8–11.0mmol/L [14]. Given the small
numbers of individuals with iIGT in lower age categories, when strati-
fying by age, all states of prediabetes were combined and deﬁned
as fasting plasma glucose of 5.6–6.9 mmol/L and/or two hour post-
challenge glucose of 7.8–11.0mmol/L. All stages of prediabetes were
deﬁned by plasma glucose measurements and were not self-
reported. Normal glucose tolerance was deﬁned as both fasting
plasma glucose <5.6 mmol/L and a two hour post-challenge glucose
<7.8 mmol/L [14]. Plasma glucose was analyzed using the hexoki-
nase method in both studies.
The HOMA model has been widely used to estimate insulin re-
sistance and β-cell function and reﬂects the balance between glucose
and insulin in the fasting state as maintained by a feedback loop
between the liver and pancreatic β-cells [15]. Therefore, HOMAmod-
eling was used to generate estimates of inherent insulin resistance
and β-cell function in participants [15]. HOMA-β was used to
measure β-cell function and was calculated as [20 × I0(μIU/mL)/G0
(mmol/L) − 3.5]. HOMA-IR was used to measure insulin resistance
and was calculated as [I0(μIU/mL) × G0 (mmol/L)/22.5] [17].
Statistical analysis
All analyses were performed using SAS Version 9.3 (SAS Insti-
tute, Cary, NC) or SAS callable SUDAAN (version 9, Research Triangle
Institute) software. Data from NHANES and CARRS were com-
bined into a single dataset for analysis. Sampling weights for each
survey were created independently in order to maximize the rep-
resentativeness of each sample andweremaintained upon combined
analysis. Participant characteristics were stratiﬁed by sex and were
compared using conditional marginal distributions and Wald chi-
squared tests. A p-value of <0.05 was considered statistically
signiﬁcant. Weighted crude prevalence values and 95% conﬁdence
intervals were estimated by study site, sex, and age group. To obtain
plots of the percent of the population in intervals of fasting plasma
glucose, two hour post challenge glucose, and fasting insulin, we
used the 2.5 and 97.5 percentiles of the distributions of eachmeasure
as end points to deﬁne the lowest and highest groups. We then
divided the population into twelve groups of equal increments.
Polytomous logistic regression was used to estimate the age- and
sex-adjusted probability of classiﬁcation into each group and to
obtain the predicted percentages of study population [18]. Addi-
tionally, multivariable logistic regression models were used to
determine the adjusted prevalence of diabetes, total prediabetes,
iIFG, iIGT, and IFG + IGT. The models were adjusted for age, sex, BMI,
and waist circumference. Standardized polytomous logistic regres-
sion was used to compare the odds of iIFG, iIGT, IFG + IGT and
diabetes compared to normal glucose tolerance by race/ethnic group.
Results
In total, 11,379 participants were included in the analysis from
four race/ethnic groups. Table 2 describes the weighted mean age,
anthropometric, and physiological characteristics of participants by
race/ethnic group and sex. In men, Hispanics were on average
younger than Asian Indians, Blacks, and Whites (p > 0.0001). In
women, Asian Indians were on average younger than Blacks and
Whites (p > 0.0001); however, there were no signiﬁcant differ-
ences in age between Asian Indians and Hispanics (p = 0.40). In both
sexes Asian Indians had the lowest mean height, weight, BMI, and
waist circumference measurements (p > 0.0001). In men, there were
no signiﬁcant differences in fasting glucose between Asian Indians
and Hispanics (p = 0.07) or Blacks (p = 0.34). However, Asian Indian
men had a higher mean fasting glucose than White men (p = 0.01).
In women, Asian Indians had the highest mean level of fasting
glucose (p > 0.01). Both Hispanic men and women had the highest
mean two hour glucose values compared to Whites and Blacks
(p > 0.0001); however, this was not signiﬁcantly different com-
pared to Asian Indians (men, p = 0.22; women, p = 0.67). In both
sexes, Asian Indians had the lowest measures of log fasting insulin,
and log HOMA-IR (p > 0.0001). In men, Asian Indians had the lowest
mean levels of log HOMA-β compared to Whites and Hispanics
(p > 0.0001); however, this was not signiﬁcantly different com-
pared to Blacks (p = 0.22). Asian Indian women had the lowest values
of log HOMA-β (p > 0.0001).
The crude prevalence of diabetes was highest in Asian Indians
and lowest in Whites (Table 3). Adjustment for age resulted in a
greater difference in diabetes prevalence between Asian Indians and
Whites. Additional adjustment for age, BMI, and waist circumfer-
ence resulted in a diabetes prevalence that was approximately 3
times as high among Asian Indians thanWhites in both sexes. When
stratiﬁed by age, in both sexes, Asian Indian participants had the
highest diabetes prevalence in all age categories (Fig. 1a).
Asian Indians had the lowest crude prevalence of prediabetes,
followed by Blacks, Hispanics, andWhites. After adjustment for age,
BMI, and waist circumference, the difference in prediabetes prev-
alence between Asian Indians and other race/ethnic groups was
attenuated, especially inwomen. In age-speciﬁc analyses, the prev-
alence of prediabeteswas the lowest inAsian Indians in all age groups
and both sexes (Fig. 1b). When prediabetes was assessed by dis-
tinct state, Asian Indian men had the lowest crude prevalence of
iIFG, followed by Blacks, Hispanics, and Whites. This remained the
case after adjustment for age, BMI, and waist circumference. Com-
pared toWhite, Black, and Hispanicmen, Asian Indianmen had the
highest prevalence of iIGT. This result persisted after adjustment
for age, BMI, and waist circumference. Asian Indian men also had
the lowest prevalence of IFG + IGT compared to White, Black, and
Hispanic men. While adjustment for age, BMI, and waist circum-
ference attenuated IFG + IGT prevalence inWhite men, it increased
IFG + IGT prevalence in Black, Hispanic and Asian Indian men.
However, this difference was only signiﬁcant in Asian Indian men.
Asian Indian women had a slightly, but not signiﬁcantly, lower
crude prevalence of iIFG compared to White, Black, and Hispanic
women. After adjustment for age, BMI, and waist circumference,
Asian Indian women had the highest prevalence of iIFG compared
to White, Black, and Hispanic women. However, this difference was
not signiﬁcant. Compared toWhite, Black and Hispanic women, Asian
Indian women had the lowest crude prevalence of iIGT and IFG + IGT.
This remained the case after iIFGwas adjusted for age, BMI, andwaist
circumference. Similar adjustments resulted in a decreased prev-
alence of IFG + IGT in White and Black women and an increased
prevalence in Hispanic and Asian Indian women; however, these
differences were not signiﬁcant.
In examining the distributions of fasting plasma glucose (Fig. 2a),
compared toWhites, Asian Indians had a higher probability of being
classiﬁed in the <4.6 mmol/L, 4.6 mmol/L (p < 0.01) and 4.8 mmol/L
(p = 0.03) ranges and had a signiﬁcantly lower probability of being
classiﬁed in the 5.4–6.0 mmol/L ranges (p ≤ 0.01). When com-
pared to Blacks, Asian Indians had a higher probability of being
classiﬁed in the <4.6mmol/L (p ≤ 0.01) range and a signiﬁcantly lower
probability of being classiﬁed in the 5.4 mmol/L (p = 0.03) and
5.6 mmol/L (p ≤ 0.01) as well as the 6.4 and ≥6.6 mmol/L (p ≥ 0.01)
ranges. In comparison to Hispanics, Asian Indians had a higher
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probability of being classiﬁed in the <4.6–5.0 mmol/L (p ≤ 0.01)
ranges and a lower probability of being classiﬁed in the 5.2 mmol/L
(p = 0.02) and the 5.4–6.0mmol/L (p ≤ 0.01) ranges of fasting glucose.
For two hour post challenge glucose distributions (Fig. 2b), com-
pared to Whites, Asian Indians had a signiﬁcantly lower probability
of being classiﬁed at the lowest point of the distribution and a sig-
niﬁcantly higher probability of being classiﬁed at the highest end
(p ≤ 0.01). When compared to Blacks, Asian Indians were more likely
to be classiﬁed at the 12.0 mmol/L (p = 0.01) and the ≥13.0 mmol/L
(p ≥ 0.01) ranges of the distribution, and in comparison to Hispan-
ics, Asian Indians were more likely to be classiﬁed between the 5.0–
6.0 mmol/L and at the highest end of the distribution (p = 0.02) and
less likely to be classiﬁed between the 7.0mmol/L (p = 0.02) and the
9 mmol/L (p ≤ 0.01) ranges of two hour glucose.
In comparing the distribution of fasting insulin (Fig. 2c), com-
pared toWhites, Asian Indians had a signiﬁcantly higher probability
of being classiﬁed in the lowest three categories (p ≥ 0.01, 0.01 and
>0.01 respectively) and a signiﬁcantly lower probability of being clas-
siﬁed in the 102.5–167.8 pmol/L (p > 0.01), the 184.1 pmol/L (p = 0.03)
and the ≥200.5 pmol/L (p = 0.01) ranges. In comparison to Blacks,
Asian Indians had a signiﬁcantly higher probability of being clas-
siﬁed in the <37.1–53.5 mmol/L (p > 0.01) range and a signiﬁcantly
lower probability of being classiﬁed at 86.2 pmol/L (p = 0.02) and
between 118.8–≥200.5 pmol/L (p ≤ 0.01, 0.02, 0.01, 0.03, <0.01 and
<0.01, respectively) ranges. When compared to Hispanics, Asian
Indians again had a signiﬁcantly higher probability of being clas-
siﬁed in the <37.1–53.5 pmol/L range (p < 0.01) and a signiﬁcantly
lower probability of being classiﬁed in the 102.5–151.5 pmol/L
(p = 0.01, >0.01, 0.02, and 0.02 respectively) as well as the 184.1–
≥200.5 (p = 0.01 and <0.01) ranges of fasting insulin.
Table 4 details the odds of iIFG, iIGT, IFG + IGT and diabetes in
Whites, Blacks and Hispanics compared to Asian Indians. After ad-
justing for age and sex, Whites, Blacks and Hispanics were 70%, 49%
and 20% less likely than Asian Indians to have diabetes, respective-
ly, and were 69%, 45%, and 150% more likely to have IFG + IGT.
Compared to Asian Indians, Whites and Hispanics were 13% and 57%
more likely to have iIGT, respectively; however, Blacks were 18% less
likely. The adjustment for BMI resulted in an increase in the odds
of diabetes in all race/ethnic groups compared to Asian Indians. The
adjustment for BMI also resulted in and attenuation of the odds of
IFG + IGT, iIGT, and iIFG in all race/ethnic groups compared to Asian
Indians, as well as a reversal of the point estimate comparing the
Table 2
Weighted characteristics of participants aged 20–75 years by race/ethnicitya
Men NHANES White NHANES Black NHANES Hispanic CARRS Asian Indian
N 1481 736 994 2067
Age (mean year) 46.0 ± 0.6 43.0 ± 0.6 39.5 ± 0.5 42.4 ± 0.5
(44.9, 47.2) (41.9, 44.1) (38.5, 40.5) (41.6, 43.8)
Height (mean cm)b 178.3 ± 0.3 176.7 ± 0.3 171.3 ± 0.3 164.5 ± 0.2
(177.8, 178.9) (176.1, 177.1) (170.5, 171.7) (163.9, 164.7)
Weight (mean kg)b 91.4 ± 0.8 89.9 ± 0.9 85.9 ± 0.8 65.5 ± 0.4
(90.3, 92.6) (88.0, 91.7) (84.2, 87.5) (64.8, 66.2)
BMI (mean kg/m2)b 28.8 ± 0.2 28.6 ± 0.3 29.0 ± 0.2 24.2 ± 0.1
(28.4, 29.1) (28.1, 29.4) (28.8, 29.7) (24.0, 24.5)
Waist circumference (mean cm)b 102.6 ± 0.6 97.5 ± 0.7 101.4 ± 0.6 87.0 ± 0.4
(101.3, 103.2) (96·7, 99·5) (100.2, 102.6) (86.7, 88.1)
Fasting glucose (mmol/L)b 5.9 ± 0.1 6.0 ± 0.1 6.3 ± 0.1 6.1 ± 0.1
(5.8, 6.0) (5.8, 6.2) (6.1, 6.5) (6.0, 6.3)
2-hr glucose (mmol/L)b 6.1 ± 0.1 6.2 ± 0.1 6.9 ± 0.1 6.7 ± 0.1
(5.9, 6.3) (6.0, 6.5) (6.6, 7.2) (6.4, 6.9)
Fasting insulin (pmol/L)b 2.5 ± 0.3 2.4 ± 0.4 2.7 ± 0.4 2.1 ± 0.2
(2.4, 2.6) (2.3, 2.5) (2.6, 2.8) (2.0. 2.1)
Log HOMA-IR (μIU/mL × mmol/L)b 1.1 ± 0.4 1.0 ± 0.5 1.3 ± 0.6 0.6 ± 0.2
(1.0, 1.2) (0.9, 1.1) (1.2, 1.5) (0.6, 0.7)
Log HOMA-β (μIU/mL/mmol/L)b 4.8 ± 0.3 4.6 ± 0.5 4.8 ± 0.3 4.5 ± 0.3
(4.7, 4.8) (4.5, 4.7) (4.7, 4.8) (4.5, 4.6)
Women NHANES White NHANES Black NHANES Hispanic CARRS Asian Indian
N 1418 818 1065 2800
Age (mean year) 46.8 ± 0.4 43.7 ± 0.6 41.1 ± 0.6 40.4 ± 0.4
(45.9, 47.7) (42.5, 44.9) (39.9, 42.2) (39.6, 41.3)
Height (mean cm)b 164.0 ± 0.3 164.0 ± 0.3 157.8 ± 0.3 150.6 ± 0.1
(163.6, 164.6) (163.3, 164.4) (156.9, 158.0) (150.3, 150.9)
Weight (mean kg)b 76.4 ± 0.6 86.3 ± 0.9 73.5 ± 0.6 62.0 ± 0.4
(75.2, 77.5) (84.6, 88.1) (72.2, 74.7) (61.3, 62.7)
BMI (mean kg/m2)b 28.5 ± 0.2 32.0 ± 0.3 29.3 ± 0.3 27.3 ± 0.1
(27.9, 28.8) (31.4, 32.7) (29.1, 30.2) (27.0, 27.6)
Waist circumference (mean cm)b 95.5 ± 0.5 100.7 ± 0.7 95.6 ± 0.6 83.7 ± 0.4
(94.2, 96.3) (99.6, 102.5) (95.3, 98.0) (83.0, 84.5)
Fasting glucose (mmol/L)b 5.5 ± 0.0 5.9 ± 1.0 5.9 ± 1.0 6.3 ± 1.0
(5.4, 5.6) (5.7, 6.1) (5.7, 6.0) (6.1, 6.4)
2-hr glucose (mmol/L)b 6.2 ± 1.0 6.3 ± 0.1 6.9 ± 1.0 6.9 ± 1.0
(6.1, 6.4) (6.1, 6.5) (6.7, 7.2) (6.7, 7.1)
Fasting insulin (pmol/L)b 2.4 ± 0.4 2.7 ± 0.5 2.6 ± 0.5 2.2 ± 0.2
(2.4, 2.5) (2.6, 2.8) (2.5, 2.7) (2.1, 2.2)
Log HOMA-IR (μIU/mL × mmol/L)b 1.0 ± 0.5 1.3 ± 0.6 1.2 ± 0.5 0.8 ± 0.2
(0.9, 1.1) (1.2, 1.4) (1.1, 1.3) (0.7, 0.8)
Log HOMA-β (μIU/mL/mmol/L)b 4.8 ± 0.4 5.0 ± 0.5 4.9 ± 0.6 4.5 ± 0.3
(4.7, 4.9) (4.9, 5.0) (4.7, 4.9) (4.4, 4.5)
a Values represent mean, ± SE, and 95% CI.
b Values are adjusted for age.
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Table 3
Weighted crude and adjusted prevalence of diabetes and prediabetes by sex and race/ethnicity
NHANES White NHANES Black NHANES Hispanic CARRS Asian Indian
Men
Crude type 2 diabetes prevalence 13.1 (11.1, 15.5) 15.1 (12.1, 18.6) 16.2 (13.4, 19.3) 25.2 (22.4, 28.2)
Type 2 diabetes prevalence adjusted for age, body mass index, and waist circumference 11.9 (10.0, 14.1) 17.3 (14.1, 21.0) 21.1 (17.7, 24.8) 39.0 (34.7, 43.8)
Crude prediabetes prevalence 46.9 (43.8, 50.0) 37.8 (34.6, 41.0) 44.2 (40.1, 48.3) 18.6 (16.9, 20.4)
Prediabetes prevalence adjusted for age, body mass index, and waist circumference 46.2 (43.3, 49.3) 39.5 (35.8, 43.4) 46.0 (41.8, 50.3) 23.0 (20.1, 26.2)
Crude iIFG prevalence 35.0 (32.3, 37.8) 27.6 (24.1, 31.4) 33.6 (29.9, 37.5) 10.3 (8.3, 12.8)
iIFG prevalence adjusted for age, body mass index, and waist circumference 35.1 (32.4, 37.9) 27.8 (24.1, 31.7) 33.5 (29.9, 37.4) 11.7 (9.1, 14.9)
Crude iIGT prevalence 2.3 (1.3, 3.8) 3.5 (2.2, 5.4) 2.2 (1.4, 3.6) 5.1 (4.0, 6.5)
iIGT prevalence adjusted for age, body mass index, and waist circumference 2.1 (1.2, 3.6) 3.7 (2.4, 5.4) 2.5 (1.5, 4.1) 5.2 (3.4, 7.8)
Crude IFG + IGT prevalence 9.7 (8.3, 11.3) 6.6 (5.3, 8.4) 8.3 (6.5, 10.6) 3.2 (2.4, 4.1)
IFG + IGT prevalence adjusted for age, body mass index, and waist circumference 9.0 (7.8, 10.5) 7.8 (6.0, 10.1) 10.4 (8.3, 13.0) 5.2 (3.8, 7.2)
Women
Crude type 2 diabetes prevalence 10.3 (8.5, 12.3) 16.9 (14.0, 20.3) 15.7 (13.1, 18.8) 22.9 (20.2, 25.9)
Type 2 diabetes prevalence adjusted for age, body mass index, and waist circumference 9.6 (7.9, 11.6) 15.3 (12.6, 18.3) 19.6 (16.7, 22.9) 41.4 (37.3, 45.7)
Crude prediabetes prevalence 35.2 (32.5, 38.1) 29.1 (25.6, 32.9) 31.4 (26.8, 36.5) 24.2 (20.2, 28.6)
Prediabetes prevalence adjusted for age, body mass index, and waist circumference 35.0 (32.0, 38.1) 28.1 (24.4, 32.1) 34.4 (29.6, 39.6) 32.8 (26.8, 39.5)
Crude iIFG prevalence 21.4 (19.0, 24.1) 19.8 (16.4, 23.7) 18.0 (14.6, 21.8) 17.3 (14.1, 21.0)
iIFG prevalence adjusted for age, body mass index, and waist circumference 21.4 (18.9, 24.2) 19.5 (15.8, 23.8) 19.6 (16.0, 23.8) 24.0 (18.6, 30.4)
Crude iIGT prevalence 5.7 (4.3, 7.5) 2.8 (1.8, 4.4) 6.8 (5.1, 9.0) 2.4 (1.9, 3.0)
iIGT prevalence adjusted for age, body mass index, and waist circumference 5.8 (4.3, 7.7) 2.7 (1.6, 4.5) 7.0 (5.2, 9.4) 2.2 (1.3, 3.5)
Crude IFG + IGT prevalence 8.1 (6.5, 10.1) 6.5 (4.9, 8.5) 6.7 (5.2, 8.6) 4.5 (3.6, 5.5)
IFG + IGT prevalence adjusted for age, body mass index, and waist circumference 7.7 (6.1, 9.7) 6.1 (4.5, 8.1) 7.9 (6.3, 1.0) 7.2 (5.3, 9.7)
*Values represent weighted prevalence and 95% CI
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Figure 1. Weighted age-speciﬁc diabetes and prediabetes prevalence by sex and race/ethnicity. a) Weighted age-speciﬁc type 2 diabetes prevalence. b) Weighted age-
speciﬁc prediabetes prevalence.
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odds of IFG + IGT in Blacks to Asian Indians. The inclusion of waist
circumference in the model instead of BMI resulted in a further at-
tenuation of the odds of diabetes compared to Asian Indians in all
race/ethnic groups, as well as a greater attenuation in the odds of
IFG + IGT, iIGT, and iIFG in all race/ethnic compared to Asian Indians,
with Blacks having a comparatively lower odds of all prediabetes
states. The inclusion of Log HOMA-β in the model severely attenu-
ated the odds of diabetes in Whites and reversed the direction of
the point estimate, resulting in increased odds of diabetes in Blacks
and Hispanics compared to Asian Indians. When compared to the
model adjusting for waist circumference, the inclusion of Log
HOMA-β increased the odds of IFG + IGT, iIGT, and iIFG in all race/
Figure 2. Distribution of fasting glucose, 2 hour glucose, and fasting insulin by race/ethnicity. a) Distribution of fasting glucose (mmol/L). b) Distribution of 2 hour glucose
(mmol/L). c) Distribution of fasting insulin (pmol/L).
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ethnic groups compared to Asian Indians aside from the odds of iIGT
in Whites compared to Asian Indians, which remained the same in
the two models. Compared to the model including Log HOMA-β,
when Log HOMA-IR was added to the model the odds of diabetes
between Asian Indians and Blacks, Whites, and Hispanics were de-
creased. The odds of all prediabetes states in Blacks, Whites, and
Hispanics compared to Asian Indians were also decreased aside from
the odds of iIGT in Whites compared to Asian Indians, which was
slightly but not signiﬁcantly increased.
Discussion
We found an overall higher prevalence of diabetes in Asian
Indians living in India than in Whites, Blacks, and Hispanics living
in the US, despite lower levels of adiposity. Interestingly, we found
the prevalence of prediabetes to be lower in Asian Indians com-
pared to other ethnic groups. After adjustment for age, BMI, andwaist
circumference, the differences in diabetes prevalence became more
evident; however, the difference in prediabetes prevalence was at-
tenuated, especially in women.
It is possible that some of the increased diabetes risk in Asian
Indians is due to innate susceptibilities for impaired pancreatic β-cell
function [8–10], while in other race/ethnic groups, obesity driven
insulin resistance might be the driving factor behind increased hy-
perglycemia. This notion was further evidenced in our study, in that
the inclusion of Log HOMA-β in polytomous regression models re-
sulted in a greater odds of diabetes in Blacks and Hispanics compared
to Asian Indians, whereas the inclusion of Log HOMA-IR did not.
However, when Log HOMA-IR was included in polytomous logis-
tic regressionmodels, the odds of all prediabetes states were severely
attenuated in Blacks, Whites, and Hispanics compared to Asian
Indians, and in some instances the point estimates were reversed,
resulting in a greater odds of iIFG in Asian Indians compared to Blacks
and Hispanics, a greater odds of iIGT in Asian Indians compared to
Whites and Blacks, and a greater odds of IFG + IGT in Asian Indians
compared to all other race/ethnic groups. Results of our study also
indicated that amongst all race/ethnic groups, Asian Indians had the
highest probability of being classiﬁed in the lowest ranges of fasting
insulin, thereby suggesting differences in insulin sensitivity com-
pared to Whites, Blacks, and Hispanics.
While the ﬁndings of our study point to a lower overall preva-
lence of prediabetes in Asian Indians living in India compared to
White, Black, and Hispanic ethnic groups in the US, we noted dif-
ferences in the prediabetes prevalence by prediabetes state and sex.
In particular, Asian Indian men had a lower prevalence of iIFG and
IFG + IGT compared to White, Black and Hispanic men, but a higher
prevalence of iIGT. Additionally, Asian Indian women had a similar
prevalence of iIFG compared to White, Black, and Hispanic women;
however, they had a lower prevalence of iIGT and IFG + IGT. Previ-
ous studies have noted a higher prevalence of iIFG in men compared
to women [16,19] as was the case in our study when assessing
Whites, Blacks, and Hispanics. However, in the case of Asian Indians,
the prevalence of iIFG was 7% higher in women than in men. These
results are in concordance with another study assessing the prev-
alence of impaired fasting glucose and impaired glucose tolerance
in individuals living in urban India that similarly reported a higher
prevalence of IFG in women compared to men [20]. Therefore, there
may be ethnic differences in the distribution of impaired fasting
Table 4
Weighted risk factors associated with prediabetes and diabetes
Model IFG IGT IFG/IGT T2DM
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Age group,a sex, race/ethnicity
Age group 1.52 (1.52, 1.52) 1.51 (1.51, 1.51) 2.20 (2.20, 2.20) 3.10 (3.10, 3.10)
Sex 0.42 (0.42, 0.42) 1.52 (1.52, 1.52) 0.57 (0.57, 0.58) 0.54 (0.54, 0.54)
White vs. Asian Indian 1.76 (1.74, 1.77) 1.13 (1.11, 1.14) 1.69 (1.67, 1.72) 0.30 (0.30, 0.31)
Black vs. Asian Indian 1.50 (1.48, 1.51) 0.82 (0.81, 0.84) 1.45 (1.43, 1.48) 0.51 (0.51, 0.51)
Hispanic vs. Asian Indian 2.19 (2.17, 2.21) 1.57 (1.54, 1.59) 2.50 (2.46, 2.54) 0.80 (0.79, 0.81)
Age group, sex, BMI, race/ethnicity
Age group 1.45 (1.45, 1.45) 1.44 (1.44, 1.44) 2.12 (2.12, 2.12) 3.12 (3.12, 3.12)
Sex 0.41 (0.41, 0.41) 1.51 (1.51, 1.51) 0.53 (0.53, 0.53) 0.45 (0.45, 0.45)
BMI 1.01 (1.01, 1.01) 1.05 (1.05, 1.05) 1.12 (1.12, 1.12) 1.17 (1.17, 1.17)
White vs. Asian Indian 1.47 (1.45, 1.48) 1.07 (1.05, 1.09) 1.24 (1.22, 1.26) 0.19 (0.18, 0.19)
Black vs. Asian Indian 1.09 (1.08, 1.10) 0.71 (0.70, 0.73) 0.88 (0.86, 0.89) 0.24 (0.24, 0.25)
Hispanic vs. Asian Indian 1.74 (1.72, 1.75) 1.42 (1.40, 1.44) 1.73 (1.70, 1.76) 0.46 (0.46, 0.47)
Age group, sex, waist circumference, race/ethnicity
Age group 1.37 (1.37, 1.37) 1.40 (1.40, 1.40) 1.96 (1.96, 1.96) 2.77 (2.77, 2.77)
Sex 0.48 (0.48, 0.48) 1.65 (1.64, 1.65) 0.69 (0.69, 0.69) 0.70 (0.70, 0.70)
Waist circumference 1.03 (1.03, 1.03) 1.02 (1.02, 1.02) 1.05 (1.05, 1.05) 1.07 (1.07, 1.07)
White vs. Asian Indian 1.20 (1.19, 1.21) 0.92 (0.91, 0.94) 0.86 (0.84, 0.87) 0.10 (0.10, 0.10)
Black vs. Asian Indian 0.99 (0.98, 0.99) 0.64 (0.63, 0.65) 0.69 (0.68, 0.70) 0.16 (0.16, 0.17)
Hispanic vs. Asian Indian 1.49 (1.48, 1.50) 1.26 (1.24, 1.28) 1.31 (1.29, 1.34) 0.30 (0.30, 0.30)
Age group, sex, HOMA-β, race/ethnicity
Age group 1.50 (1.50, 1.50) 1.48 (1.48, 1.49) 2.23 (2.23, 2.23) 3.10 (3.09, 3.10)
Sex 0.54 (0.54, 0.54) 1.24 (1.23, 1.24) 0.50 (0.49, 0.50) 0.73 (0.73, 0.73)
Log HOMA-β 0.91 (0.91, 0.91) 1.15 (1.15, 1.16) 1.39 (1.39, 1.39) 0.65 (0.65, 0.65)
White vs. Asian Indian 1.78 (1.76, 1.80) 0.92 (0.90, 0.93) 1.19 (1.17, 1.21) 0.85 (0.84, 0.86)
Black vs. Asian Indian 1.28 (1.27, 1.29) 0.75 (0.74, 0.76) 1.26 (1.24, 1.28) 1.71 (1.68, 1.72)
Hispanic vs. Asian Indian 1.97 (1.95, 1.99) 1.07 (1.05, 1.09) 1.49 (1.46, 1.51) 2.94 (2.90, 3.0)
Age group, sex, HOMA-IR, race/ethnicity
Age group 1.62 (1.62, 1.62) 1.47 (1.46, 1.47) 2.53 (2.53, 2.53) 4.33 (4.32, 4.33)
Sex 0.50 (0.50, 0.50) 1.3 (1.2, 1.3) 0.46 (0.46, 0.46) 0.66 (0.66, 0.66)
Log HOMA-IR 2.49 (2.49, 2.49) 1.16 (1.16, 1.16) 4.55 (4.55, 4.56) 7.61 (7.60, 7.61)
White vs. Asian Indian 1.06 (1.05, 1.07) 0.93 (0.91, 0.94) 0.53 (0.52, 0.54) 0.16 (0.16, 0.17)
Black vs. Asian Indian 0.70 (0.70, 0.71) 0.76 (0.75, 0.77) 0.55 (0.55, 0.56) 0.33 (0.32, 0.33)
Hispanic vs. Asian Indian 0.16 (0.16, 0.17) 1.05 (1.03, 1.07) 0.58 (0.57, 0.59) 0.49 (0.48, 0.49)
a Age was deﬁned as a categorical variable. The age groups represented were 20–34, 35–44, 45–54, 55–74, with 20–34 used as the referent group.
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glucose by sex; however, themechanisms behind this are not known
and further studies in this area are warranted.
Our study directly compared the prevalence of diabetes and pre-
diabetes four race/ethnic groups using two large population-
based surveys using both self-report and laboratorymeasures. While
glucose and insulin were analyzed in different laboratories, both used
the same assays for analysis, thereby reducing intra-laboratory bias.
Additionally, assays from the laboratory in Chennai have been run
against a reference laboratory in the US and show a high concor-
dance of r = 0.945. Furthermore, while there were differences in the
sampling frames, both studies are large population-based samples
that are representative either of the US, or an urban city in India.
While they cannot be generalized to the entire Indian population,
results from our studymirror those of other population-based studies
in urban India that have noted an especially high diabetes preva-
lence [3,21–23]. Furthermore, many rural areas of India are now
starting to urbanize and experience their own increases in diabe-
tes prevalence as well [4,24,25].
In conclusion, we found that compared toWhites, Blacks and His-
panics in the US, Asian Indians in India have a higher age-speciﬁc
prevalence of diabetes in both sexes and in all adult age groups that
exists despite Asian Indians having lower adiposity measure-
ments. This suggests the contribution of non-obesity driven factors
to the disproportionate burden of disease. The results of this study
point to impaired pancreatic β-cell function as the driving force
behind the high diabetes prevalence in Asian Indians, and suggest
that Asian Indians are at high risk even at lower levels of age and
adiposity, and interventions and treatments aimed solely at im-
proving insulin resistance may not be optimal in this ethnic group.
Additionally, the higher prevalence of type 2 diabetes in Asian Indians
even in the youngest age group of 20–34 years points to the need
for population based prevention strategies that start early in life,
possibly even during youth and early adolescence. Further studies
aimed at both the pathophysiological and the socio-environmental
mechanisms of β-cell preservation early in the natural history of
disease in groupswho experience type 2 diabetes even in the absence
of obesity-driven factors are therefore warranted.
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